Literature DB >> 31423737

A GSH-Gated DNA Nanodevice for Tumor-Specific Signal Amplification of microRNA and MR Imaging-Guided Theranostics.

Nan Yan1,2,3, Lin Lin1,3, Caina Xu1,3, Huayu Tian1,3,4, Xuesi Chen1,3,4.   

Abstract

Developing tumor-responsive diagnosis and therapy strategies for tumor theranostics is still a challenge owing to their high accuracy and specificity. Herein, an AND logic gated-DNA nanodevice, based on the fluorescence nucleic acid probe and polymer-modified MnO2 nanosheets, for glutathione (GSH)-gated miRNA-21 signal amplification and GSH-activated magnetic resonance (MR) imaging-guided chemodynamic therapy (CDT) is reported. In the presence of overexpressed miRNA and GSH (tumor cells), the nanodevice can be in situ activated and release significantly amplified fluorescence signals and MR signals. Conversely, the fluorescence signal is quenched and MR signal remains at the background level with low miRNA and GSH (normal cells), efficiently reducing the false-positive signals by more than 50%. Under the guide of miRNA profiling and MR imaging, the tumor-responsive hydroxyl radical (·OH) can effectively kill tumor cells. Furthermore, the nanodevice shows catalase-like activity and glucose oxidase-like activity with the performance of O2 production and glucose consumption. This is the first time to fabricate a tumor-responsive theranostic DNA nanodevice with tumor-specific signal amplification of microRNA and GSH-activated MR imaging for CDT, potential hypoxia relief and starvation therapy, which provides a new insight for designing smart theranostic strategies.
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  DNA nanodevice; Fenton-like reaction; chemodynamic therapy; nucleic acid probes; theranostics

Mesh:

Substances:

Year:  2019        PMID: 31423737     DOI: 10.1002/smll.201903016

Source DB:  PubMed          Journal:  Small        ISSN: 1613-6810            Impact factor:   13.281


  3 in total

1.  Yolk-shell nanovesicles endow glutathione-responsive concurrent drug release and T1 MRI activation for cancer theranostics.

Authors:  Dahai Liu; Zijian Zhou; Xinyu Wang; Hongzhang Deng; Lin Sun; Haixin Lin; Fei Kang; Yong Zhang; Zhantong Wang; Weijing Yang; Lang Rao; Kuikun Yang; Guocan Yu; Jianshi Du; Zheyu Shen; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2020-03-16       Impact factor: 12.479

2.  MicroRNA-346 inhibits the growth of glioma by directly targeting NFIB.

Authors:  Yangyang Li; Jia Xu; Jiale Zhang; Jie Zhang; Jian Zhang; Xiaoming Lu
Journal:  Cancer Cell Int       Date:  2019-11-14       Impact factor: 5.722

3.  Perfluorooctyl bromide nanoemulsions holding MnO2 nanoparticles with dual-modality imaging and glutathione depletion enhanced HIFU-eliciting tumor immunogenic cell death.

Authors:  Xinping Kuai; Yuefei Zhu; Zheng Yuan; Shengyu Wang; Lin Lin; Xiaodan Ye; Yiping Lu; Yu Luo; Zhiqing Pang; Daoying Geng; Bo Yin
Journal:  Acta Pharm Sin B       Date:  2021-07-31       Impact factor: 11.413

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.